On this call, we will be discussing our financial results for the fourth quarter and full year ending December 31st, 2025, which were released earlier this morning. The non-GAAP reconciliations can be found in today's earnings press release, which is available in the investor relations section of our website. I'm pleased to report that we achieved $17.4 million in revenue from continuing operations in Q4, representing robust 21% year-over-year growth. One, continued demand for our XplorIR gas identification device by firefighters and hazmat response teams.

Two, strong initial demand for VipIR, our new product that provides simple and fast chemical analysis of solids and liquids. Most importantly, we achieved positive Adjusted EBITDA in the fourth quarter of $0.7 million, which is a remarkable improvement from the prior year's loss of $4 million. For the full year 2025, I'm proud to report that we delivered $56.2 million in revenue from continuing operations, representing strong 18% year-over-year growth and in line with our five-year CAGR performance. A key highlight was our team's execution of replacing outdated FTIR equipment with modern devices, one of our growth catalysts.

In 2025, more than 50% of device placements came from FTIR, led by the full year impact of our XplorIR device. Another highlight is our achievement of 22% year-over-year growth in recurring revenue, which represents 35% of our 2025 revenues. This growth reflects our ongoing efforts to offer more value to our customers through service, support, software, and accessory offerings, strengthening revenue visibility and long-term predictability. Our number one focus has been to increase adoption of our devices to address global threats to public health and safety.

What went well
  • Fourth-quarter revenue was $17.4 million, up 21% year over year, and the company achieved its first-ever quarter of positive adjusted EBITDA at $0.7 million (versus a $4.0 million loss a year earlier).
  • Full-year 2025 revenue was $56.2 million, up 18%, with net loss from continuing operations narrowing to $33.3 million from $53.1 million and the full-year adjusted EBITDA loss down 39% to $9.6 million.
  • Q4 net income from continuing operations was $4.4 million, versus a $16 million loss in the prior-year period.
  • VipIR shipped more than 40 units (over $3 million of revenue) in Q4; XplorIR more than doubled its placements year over year in Q4 and grew more than 40% for the full year.
  • Q4 gross margin rose to 53% from 47%, and adjusted gross margin expanded about 530 basis points to 57% on higher volume and favorable channel mix.
  • U.S. state and local revenue grew 38% to approximately $24 million (43% of full-year revenue, up from 37%); full-year recurring revenue grew 22% to $19.5 million.
  • International revenue rose to 27% of the total (from 25%) with strong demand along NATO's eastern flank; the company consolidated four federal contracting partners into one (Mountain Horse Solutions) for procurement predictability.
  • Ended 2025 with $113 million in cash and no debt, and entered 2026 with a late-stage pipeline roughly double its size at the start of 2025.
What went wrong
  • Full-year net loss from continuing operations remained large at $33.3 million, driven by non-cash goodwill impairment and contingent-consideration revaluation charges.
  • Full-year gross margin was flat year over year at 51%.
  • The full-year adjusted EBITDA was still a loss of $9.6 million, and 2026 guidance implies continued adjusted-EBITDA losses.
  • 2026 guidance assumes increased selling and marketing investment (targeted headcount) that will weigh on near-term profitability.
  • The AVCAD next phase still awaited government feedback on Smiths Detection's RFP response, with 908 Devices' component contributions likely only in the second half of 2026.
  • Recurring revenue mix dipped to 32% of revenue in Q4 as higher device placements diluted the percentage.

Guidance Changes

MetricPeriodCurrent guidance
FY2026 revenueFY2026$64.5-$67.5 million, representing 15%-20% growth over FY2025
FY2026 handheld product & service revenueFY2026grow 13%-17% ($59.5-$61.5 million), reflecting a full year of VipIR and MX908 growth
FY2026 OEM & funded partnerships (incl. contract revenue)FY2026~$3 million
FY2026 AVCAD program revenueFY2026$2-$3 million, likely in the second half of 2026
FY2026 adjusted gross marginFY2026mid-to-high 50% range, targeting at least 100 bps of expansion on higher volume
FY2026 adjusted EBITDAFY2026cut the loss roughly in half to mid-single-digit millions

Performance Breakdown

MetricYoYNote
Q4 revenue +21% to $17.4 million XplorIR, strong initial VipIR demand and state/local adoption
Full-year revenue +18% to $56.2 million FTIR products (VipIR, XplorIR) plus a full year of RedWave ownership vs. 8 months in 2024
Q4 adjusted EBITDA +$4.7M to positive $0.7 million Structural cost reductions across headcount, facilities, R&D and professional fees
Q4 adjusted gross margin 57%, +~530 bps Higher volume and a shift toward higher-ASP state/local and defense sales
State and local revenue +38% to ~$24 million (43% of revenue) More frequent, smaller, more predictable deals
Recurring revenue (full year) +22% to $19.5 million FTIR service and OEM revenues
Installed base 3,736 devices (224 shipped in Q4) Continued placements across FTIR and mass spec

Earnings Call Themes & Trends

TopicPrevious mentionCurrent periodTrend
Transformation delivering structural profitabilityTargeting Q4 adjusted-EBITDA positiveAchieved positive Q4 adjusted EBITDA of $0.7M; cost structure now 'right-sized, disciplined and fully within our control'
2026 strategic focus areas908 Devices 2.0 executionScale proven platforms, extend platform leadership, and strengthen revenue durability
FTIR replacement cycleEarly modernization traction>50% of 2025 device placements were FTIR; XplorIR +40% full year; management says it has 'only made a dent'
International / NATO demandEmergingInternational 27% of revenue; shipments to Poland, Czech Republic, Finland, Ukraine and others along NATO's eastern flank
Program revenue / AVCADAwaiting next phaseSmiths Detection responded to an RFP for ~a few hundred systems; 908 component contributions potentially in H2 2026

Q&A Summary

Why partner with Mountain Horse now, and how does it change the federal model?
Knopp said 908 continues to drive demand directly but consolidated four federal contracting partners into Mountain Horse Solutions to improve forecasting accuracy, level-load production and deliver mission-ready configured solutions faster.
Is the next-gen MX908 still on schedule for 2026 and how should we think about adoption?
Knopp confirmed the next-gen platform remains on track for a commercial launch later in 2026, though specifics are withheld for competitive reasons, with a large existing installed base to upgrade.
What are the drivers to reach the top end of the 2026 range?
Knopp and Griffith cited macro tailwinds (funding, defense budgets, NATO), state and local momentum, VipIR's full-year impact, MX908 growth and potential AVCAD contribution as multiple paths that more than double pro-forma growth versus 2025.
Beyond the ~50% adjusted-EBITDA-loss improvement, what other levers exist?
Knopp noted a better funding backdrop with 11 of 12 federal appropriations complete; Griffith reaffirmed commitment to roughly halving the ~$10 million 2025 adjusted EBITDA loss without handicapping growth.
How do Middle East or global conflicts affect federal timing and focus?
Knopp said the company is not seeing a meaningful near-term impact given the government's breadth of engagement and the growing state and local share of revenue.
Where is the incremental OpEx going and what is the return?
Griffith said increased selling and marketing (inside sales, outreach, remote demos, international channel) targets state/local (quicker payback) and international (longer game), aimed at driving revenue growth.

More on 908 Devices Inc.

Reported 2026-03-03 · figures from the 908 Devices Inc. Q4 2025 earnings call.

See how VectorShift works for your firm

Request Demo